At a Glance
- Company: Candel Therapeutics (Nasdaq: CADL)
- Location: Needham, Massachusetts
- Deal value: $100M non-dilutive funding commitment
- Focus area: CAN-2409 viral immunotherapy for prostate cancer
- Next steps: Initiate commercial launch planning post-phase 3
What happened?
Candel Therapeutics announced a $100 million financing agreement with RTW Investments on 20 February 2026 to fund the commercial launch of CAN-2409, its lead viral immunotherapy. The deal provides upfront access to funds upon completing patient enrollment in the phase 3 CAN-005 trial for intermediate-risk prostate cancer. This supports regulatory filings and market entry following positive interim data.
Why does it matter?
Prostate cancer affects over 1.4 million men annually worldwide, with limited options beyond surgery or radiation for intermediate-risk cases. CAN-2409’s mechanism—inducing immunogenic cell death and systemic anti-tumor immunity—offers a one-time treatment with durable responses, potentially disrupting standard care and expanding Candel’s virotherapy platform across solid tumors.
Who’s behind it?
Candel Therapeutics develops multimodal biological immunotherapies. RTW Investments, a life sciences specialist, provides the non-dilutive capital. CEO Paul Peter Tak highlighted the partnership’s role in accelerating patient access.
How was it achieved?
CAN-2409 uses an adenovirus engineered to express HSV thymidine kinase, injected intratumorally with prodrug valacyclovir to trigger tumor cell lysis and immune activation. Phase 2 data showed 71% cancer control at five years; phase 3 enrollment nears completion with FDA fast-track designation.
What’s next?
Funds enable BLA submission targeted for 2027, commercial infrastructure buildout, and advancement of CAN-2409 in non-small cell lung cancer alongside next-gen candidates like CAN-441. Manufacturing scale-up underway.